Indication
Metastases
8 clinical trials
5 products
3 drugs
Clinical trial
Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckStatus: Completed, Estimated PCD: 2010-12-15
Product
PanitumumabClinical trial
An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast CancerStatus: Completed, Estimated PCD: 2014-02-27
Product
AMG 386Clinical trial
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin ChemotherapyStatus: Completed, Estimated PCD: 2007-01-01
Clinical trial
An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2008-10-01
Clinical trial
A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Product
iCasp9M28z T cell infusionsDrug
cyclophosphamideDrug
pembrolizumabClinical trial
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone MetastasesStatus: Recruiting, Estimated PCD: 2024-04-01
Product
External Beam RadiationClinical trial
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver MetastasesStatus: Recruiting, Estimated PCD: 2026-03-31
Product
Yttrium-90Clinical trial
Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard® 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.Status: Active (not recruiting), Estimated PCD: 2027-09-01
Drug
LHRH agonist